Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Blood and lymphatic system disorders – page 12

  • 1 206 clinical trials
  • 460 recruiting
  • 364 conditions
  • 27 countries

Conditions in this area

364 conditions with trials, the busiest first

Plasma cell myeloma164Acute myeloid leukaemia132Chronic lymphocytic leukaemia80Myelodysplastic syndrome53Diffuse large B-cell lymphoma51Acute lymphocytic leukaemia43Plasma cell myeloma refractory42Follicular lymphoma41Mantle cell lymphoma33Myelofibrosis32B-cell small lymphocytic lymphoma29Chronic myeloid leukaemia29Immune thrombocytopenia27B-cell lymphoma25Factor VIII deficiency25Sickle cell disease25Hodgkin's disease23Non-Hodgkin's lymphoma22Haematological malignancy20Marginal zone lymphoma17Paroxysmal nocturnal haemoglobinuria17B-cell lymphoma refractory16B-cell type acute leukaemia16Anaemia14+340

Clinical trials in Blood and lymphatic system disorders

1 206 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 206 clinical trials

B-cell small lymphocytic lymphoma refractory+1

Recruiting

Study of sonrotoclax plus obinutuzumab or rituximab compared to venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:BeOne Medicines AG

Chronic lymphocytic leukaemia refractory+13

Recruiting

Study of BGB-16673 in combination with drug therapy for patients with relapsed or refractory B-cell malignancies

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BGB-16673
  • Sponsor:BeOne Medicines AG

Acute myeloid leukaemia

Recruiting

Study of Bleximenib, Venetoclax, and Azacitidine Treatment for Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Janssen Cilag International

Haematological malignancy

Recruiting

Study of Reduced Cyclophosphamide Dose After Haploidentical Stem Cell Transplantation in Patients with Blood Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Assistance Publique Hopitaux De Paris

Follicular lymphoma

Recruiting

Study Comparing Golcadomide and Rituximab with Other Treatments for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Celgene Corp.

Sickle cell anaemia

Recruiting

Evaluating Morphine Effectiveness Based on Kidney Function in Patients with Sickle Cell Disease During Vaso-occlusive Crisis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Iohexol
  • Sponsor:Centre Hospitalier Regional Universitaire De Tours

Factor IX deficiency

Recruiting

Study of Etranacogene Dezaparvovec (CSL222) in Adolescent Males with Severe or Moderately Severe Hemophilia B

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Etranacogene Dezaparvovec
  • Sponsor:CSL Behring LLC

Mantle cell lymphoma

Recruiting

Study on the Effectiveness and Safety of Pirtobrutinib and Rituximab for Untreated Adult Patients with Indolent Mantle Cell Lymphoma

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib
  • Sponsor:Fundacion Geltamo

Immune thrombocytopenia

Recruiting

Study on the Safety and Effectiveness of Pirtobrutinib for Adults with Immune Thrombocytopenia

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Pirtobrutinib
  • Sponsor:Eli Lilly & Co.

Chronic lymphocytic leukaemia+1

Recruiting

Study Comparing BGB-16673 to Drug Combinations for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Treated with BTK and BCL2 Inhibitors

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:BGB-16673
  • Sponsor:BeOne Medicines AG

Mantle cell lymphoma

Recruiting

Study of Acalabrutinib with R-CHOP for Patients with Untreated Mantle Cell Lymphoma in Spain

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Astrazeneca Farmaceutica Spain S.A.

Haematological malignancy

Recruiting

Study Comparing High-Dose and Standard-Dose Inactivated Influenza Vaccines in Adults with Blood Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227)
  • Sponsor:CHU De Liege

Substances studied in this area

The therapies tested most often in Blood and lymphatic system disorders trials.

Dexamethasone139 clinical trialsRituximab121 clinical trialsVenetoclax115 clinical trialsCyclophosphamide99 clinical trialsLenalidomide99 clinical trialsCytarabine77 clinical trialsDaratumumab74 clinical trialsAzacitidine65 clinical trialsBortezomib64 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.